A Biotech Company is proud to advance its flagship research programme, supported by the British Council and delivered in collaboration with the UCL Great Ormond Street Institute of Child Health (London, UK) and Princess Nourah bint Abdulrahman University (Riyadh, Saudi Arabia).

This partnerships bring together complementary world-class strengths in immunology, paediatrics, and translational medicine, with strong links to child health through Great Ormond Street and global perspectives through collaboration with the world’s largest all-female university. This integrated approach ensures that our research remains grounded in real-world clinical relevance while advancing cutting-edge molecular and analytical science.

Our research explores how microbiome-derived metabolites and probiotic signals shape T cell immunity, with a focus on understanding and controlling immune responses through metabolic inputs. By applying advanced technologies including transcriptomics, metabolomics, and functional cell modelling, we aim to define how these signals influence immune activation, regulation, and long-term biological outcomes.

Building on this foundation, we are investigating how metabolite-driven immune modulation can enhance next-generation cell therapies such as CAR-T, improving their precision, safety, and durability. At the same time, this work opens broader opportunities to understand how immune–metabolic interactions influence human health across the life course, from early development through to disease.

This programme reflects A Biotech Company’s commitment to translating fundamental biological insights into impactful, scalable solutions. By integrating global collaboration, advanced technologies, and clinically relevant questions, we are contributing to a future where immune responses can be precisely guided to improve outcomes for patients worldwide.